Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that all-too familiar routine of online calls and deadlines has returned. Moreover, there is anticipation over a looming FDA decision for a controversial Alzheimer’s drug. So time to get cracking and a brew a cup of stimulation, yes? Our choice today is butter pecan. Meanwhile, here are a few items of interest to help you on your journey. Hope all goes well today and you conquer the world. …

AstraZeneca (AZN) filed a lawsuit in the U.K. against GlaxoSmithKline (GSK), saying a 2012 licensing agreement over the Zejula cancer drug was breached and, therefore, it should have a greater share of sales, The Sunday Times reports. Glaxo acquired the medication, which is used to combat ovarian and other forms of cancer, as part of its $5 billion acquisition of Tesaro in late 2018. The drug generated $480 million in sales last year and was developed, in part, by technology owned by AstraZeneca and licensed to Glaxo.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.